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ABSTRACT
Cancer is a group of diseases characterized by abnormal cell growth. Old cells do not die
and grow uncontrollably, forming a mass of tissue, called a tumor. In order to understand this
abnormal cell growth, there have been various efforts to model the interactions between different
molecules and pathways that initiate and drive cell proliferation. In this work, we analyze Bayesian
and Boolean techniques that can aid in modeling different cancer networks and infer the drug
combinations that can effectively kill tumor cells.
Signaling pathways supervise cellular processes such as growth, differentiation, and death. In
healthy cells, these processes are tightly regulated, however, in cancerous cells, mutations in cru-
cial genes often lead to irregularities in these processes and eventually cancer. In this work, we
study pathways and genes characterizing Breast cancer, Pancreatic cancer, and Lung cancer. We
make use of biological literature to construct the pathways and then use mathematical modeling
techniques to analyze and rank different therapeutic interventions. We first develop a Bayesian
network of Breast cancer and using a messaging passing algorithm, we infer the network and rank
drugs according to their ability to induce apoptosis. We then model the signaling network and
mutations of Pancreatic cancer using a multi-fault Boolean framework and simulate the network
to theoretically assess the efficacy of drug combinations. Finally, we use a modified Boolean
approach to mathematically model feedback loops in Lung cancer and determine the drug combi-
nations that produce cell death for the majority of mutations.
Our theoretical analyses point out that drug combinations containing Cryptotanshinone, a com-
pound found in traditional Chinese herbs, result in significantly increased cell death in each of
Breast, Pancreatic, and Lung cancer pathways. We corroborated our theoretical results with ex-
periments on MCF-7 breast cancer cell lines, Human Pancreatic Cancer (HPAC) cell lines, H2073
and SW900 lung cancer cell lines.
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1. INTRODUCTION ∗
Breast Cancer is the second leading cause of cancer death among US women, hence identify-
ing potential drug targets is an ever increasing need. In Section 2, we integrate existing biological
information with graphical models to deduce the significant nodes in the Breast Cancer signaling
pathway. We make use of biological information from the literature to develop a Bayesian network.
Using the relevant gene expression data we estimate the parameters of this network. Then, using a
messaging passing algorithm, we infer the network. The inferred network is used to quantitatively
rank different interventions for achieving a desired phenotypic outcome. The particular phenotype
considered here is the induction of apoptosis. The theoretical analysis pinpoints to the role of Cryp-
totanshinone, a compound found in traditional Chinese herbs, as a potent modulator for bringing
about cell death in the treatment of cancer. Using a mathematical framework, we showed that the
combination therapy of mTOR and STAT3 genes yields the best apoptosis in Breast Cancer. The
computational results we arrived at are consistent with the experimental results that we obtained
using Cryptotanshinone on MCF-7 breast cancer cell lines and also by the past results of others
from the literature, thereby demonstrating the effectiveness of our model.
The number of deaths associated with Pancreatic Cancer has been on the rise in the United
States making it an especially dreaded disease. The overall prognosis for pancreatic cancer pa-
tients continues to be grim because of the complexity of the disease at the molecular level in-
volving the potential activation/inactivation of several diverse signaling pathways. In Section 3,
we first model the aberrant signaling in pancreatic cancer using a multi-fault Boolean Network.
Thereafter, we theoretically evaluate the efficacy of different drug combinations by simulating this
∗Parts of this section are reprinted with permission from H. Vundavilli, A. Datta, C. Sima, J. Hua, R. Lopes, and
M. Bittner, “Bayesian Inference Identifies Combination Therapeutic Targets in Breast Cancer,” IEEE Transactions on
Biomedical Engineering, vol. 66, no. 9, pp. 2684-2692, 2019, doi: 10.1109/TBME.2019.2894980 c© 2019 IEEE; and
H. Vundavilli, A. Datta, C. Sima, J. Hua, R. Lopes, and M. Bittner, “In Silico Design and Experimental Validation of
Combination Therapy for Pancreatic Cancer,” IEEE/ACM Transactions on Computational Biology and Bioinformatics,
vol. 17, no. 3, pp. 1010-1018, 2020, doi: 10.1109/TCBB.2018.2872573 c© 2020 IEEE; and H. Vundavilli, A. Datta, C.
Sima, J. Hua, R. Lopes, and M. Bittner, “Cryptotanshinone Induces Cell Death in Lung Cancer by Targeting Aberrant
Feedback Loops,” in IEEE Journal of Biomedical and Health Informatics, vol. 24, no. 8, pp. 2430-2438, 2020, doi:
10.1109/JBHI.2019.2958042 c© 2020 IEEE.
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boolean network with drugs at the relevant intervention points and arrive at the most effective
drug(s) to achieve cell death. The simulation results indicate that drug combinations containing
Cryptotanshinone, a traditional Chinese herb derivative, result in considerably enhanced cell death.
These in silico results are validated using wet lab experiments we carried out on Human Pancreatic
Cancer (HPAC) cell lines.
Signaling pathways oversee highly efficient cellular mechanisms such as growth, division, and
death. These processes are controlled by robust negative feedback loops that inhibit receptor-
mediated growth factor pathways. Specifically, the ERK, the AKT, and the S6K feedback loops
in Lung Cancer attenuate signaling via growth factor receptors and other kinase receptors to reg-
ulate cell growth. Irregularity in any of these supervised processes can lead to uncontrolled cell
proliferation and possibly cancer. These irregularities primarily occur as mutated genes, and an
exhaustive search of the perfect drug combination by performing experiments can be both costly
and complex. Hence, in Section 4, we model the Lung Cancer pathway as a Modified Boolean
Network that incorporates feedback. By simulating this network, we theoretically predict the drug
combinations that achieve the desired goal for the majority of mutations. Our theoretical analysis
identifies Cryptotanshinone, a traditional Chinese herb derivative, as a potent drug component in
the fight against cancer. We validated these theoretical results using multiple wet lab experiments
carried out on H2073 and SW900 lung cancer cell lines.
2
2. BAYESIAN INFERENCE IDENTIFIES COMBINATION THERAPEUTIC TARGETS IN
BREAST CANCER ∗
2.1 Introduction
Cancer is a collection of diseases characterized by out-of-control cell growth. Cancer devel-
ops when the body’s normal control system stops working. Old cells do not die and grow out of
control, forming new, aberrant cells. These extra cells may form a mass of tissue, called a tu-
mor. Despite major progress over the last 40 years, it is estimated that in 2017 alone over 250,000
women will be diagnosed with breast cancer and more than 40,000 will die just in the United States
[4]. This calls for safe, contemporary and effective tools in the battle against breast cancer. One
way to approach several problems in Medicine and other life sciences is as a control problem, with
the objective being to find methods to drive an undesirable state of a Gene Regulatory Network
(GRN) into another, more desirable one, by means of an intervention, such as a therapeutic treat-
ment. The rationale for this is that if we can build a good model and find the targets with the
most “significance”, we may be able to design drugs for diseases, such as cancer, resulting from
gene misregulations. In this vein, there have been numerous attempts at modeling genetic regula-
tory networks, such as Boolean networks [5, 6], Differential equations [7], Probabilistic Boolean
networks [8] and Bayesian networks [9, 10, 11].
In this work, we describe a methodology that utilizes current biological knowledge from the
literature to build a GRN model and integrates this knowledge with experimental Genomic data
using a Bayesian Network based approach. Bayesian Networks are a class of Directed Acyclic
Graphs(DAGs) that encode independencies in a given network. They are suitable to the problem
since they can be used to represent causal relationships, analogous to the interactions in biological
signaling pathways. In the given network, our interest is in selecting genes which can be used as
modulators in order to drive the pathway dynamics to a desirable state. As the network grows in
∗Parts of this section are reprinted with permission from H. Vundavilli, A. Datta, C. Sima, J. Hua, R. Lopes, and
M. Bittner, “Bayesian Inference Identifies Combination Therapeutic Targets in Breast Cancer,” IEEE Transactions on
Biomedical Engineering, vol. 66, no. 9, pp. 2684-2692, 2019, doi: 10.1109/TBME.2019.2894980 c© 2019 IEEE
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size, this modulator selection problem becomes intractable. Fortunately, we have a polynomial-
time algorithm called Pearl’s Message-Passing Algorithm for performing modulator selection in
Bayesian networks. We apply this algorithm to the Breast Cancer pathway in the human body to
derive effective drug targets related to breast cancer.
2.2 Methodology
2.2.1 Bayesian Networks
Bayesian networks (BNs), also known as belief networks, belong to the family of probabilistic
graphical models (PGMs). In the last decade, BNs have become extremely popular and have been
used for applications in various areas, such as machine learning [12], speech recognition [13],
bioinformatics [9], plant genomics [14], etc.
Interactions in gene regulatory networks are usually sparse. i.e., each gene interacts with a
very small number of genes compared to the total number of genes in the network. Due to this
sparseness, the generated BN models are easy to categorize, which promises well for both recon-
struction and visualization scalability, and this makes BN models a promising tool for the analysis
of gene regulatory networks [15, 16]. Also, biological systems are naturally stochastic, and the
probabilistic nature of Bayesian networks is well suited for capturing the uncertainties involved in
gene networks.




, where G is the DAG over the set of random variables X. The
nodes X1, X2, ..., Xn in G represent random variables, and the edges in G represent the direct
dependencies between them. In a BN, each variable is independent of its nondescendents in the
graph given the state of its parents, which is consistent with a Markovian property, where the CPD
at each node depends only on its parents. The second component θ denotes the set of parameters
of the network. Accordingly, G defines a unique joint probability distribution(JPD) over X given
by:
P (X1, X2, ..., Xn) =
∏
P (Xi|Pa(Xi)) (2.1)
where Pa(Xi) are the parents of Xi.
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In a biological application, we can use the signaling pathway knowledge available in the bi-
ological literature to construct the graph skeleton according to which the JPD of our model gets
factorized.
2.2.2 Integrating Gene Expression Data
Once we obtain the graph structure G of the Bayesian network, we proceed to update the model
parameters using gene expression data. Gene expression data obtained from public repositories
such as NCBI usually consists of expressions of key genes measured across different experiments,
and results in a matrix with raw data as shown in Table 2.1.
Table 2.1: Example gene expression table. (Reprinted from [1])
Exp1 Exp2 . . . Expm
Gene1 0.34 0.49 ... 0.05
Gene2 0.86 0.62 ... 0.35
...
... . . .
Genen 0.44 0.29 ... 0.87
We use a binary quantization of gene expression data. There are several advantages to doing so
such as enhanced noise robustness and reduction of computational complexity. Gene expression
levels are heavily skewed in linear scale. Hence, using a standard threshold for discretizing mul-
tiple genes would lead to biasing error. Therefore, for each gene, assuming the gene expression
data is normally distributed, we used a maximum likelihood estimator for the mean µ, and used it
as the threshold to discretize the expression data for that specific gene. Expression values above
the threshold are assigned a 1 value and those below are assigned a 0 value. The choice of this
threshold is also justified using the Central Limit Theorem and the Law of large numbers. We next
integrate the gene expression data with the Bayesian model.
Hoff [17] showed that whenever we have a conjugate prior, the posterior distribution belongs
to the same family of distributions as the prior. The beta distribution is known to be a conjugate
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to the binomial likelihood, hence, if we choose the prior to be a Beta distribution, the conditional
posterior probability distributions of nodes are again given by a beta distribution, i.e.
P (p|X) ∼ Beta(ᾱX , β̄X) (2.2)
where ᾱX = (αX +m), β̄X = (βX +n−m), n is the number of observations, m is the number
of 1’s in the data of X and αX , βX are the shape parameters of the Beta distribution.




Initially, we assign a prior for all nodes as Beta(1,1), which is a uniform distribution over the
finite interval [0,1]. Using Equation (2.2), we update the prior using the gene expression data
to obtain the posterior distribution. With the posterior distribution in hand, we can calculate the
posterior mean which is the expected value of each state of a target node conditioned on each
possible combination of states of its parent nodes. As more data are observed, we can update the
values of ᾱX and β̄X so that the posterior probabilities approach the true underlying distribution.
When this occurs, the expected values converge to the CPDs of our Bayesian network. A simple
algorithm implementing the above procedure of integrating gene expression data to calculate the
CPDs is given in Algorithm 1 below.
With the Bayesian network graph G and its CPDs calculated, we want to identify the most
significant nodes, which when used as modulators will drive our network to the desired output.
2.2.3 Significant Genes
Biologically, a gene with a stronger effect on a target (gene or output) has a higher chance of
desirably affecting the latter as compared to other genes that have only minimal effects. Not all
genes have the same influence in a network and hence identifying the gene(s) which have high
“significance” is of utmost importance while trying to carry out drug design. For example, p53 is a
6
1 Calculating the CPDs of a Bayesian Network
1: procedure PROBABILITIES(G, S) . Input graph matrix G and dataset S
2: for each column in S do
3: find the mean
4: for each row in the column do








13: for each node in G do
14: find its parents and store them
15: the number of conditional probabilities = 2(number of parents)
16: for each data-point of the node do
17: compare with the data-points of its parents
18: if match then count← count + 1
19: using count calculate ᾱX and β̄X from (2.2)
20: end if




well known tumor suppressor gene, whereas p73 another tumor suppressor gene is less productive
in activating apoptosis compared to p53 [18].
Given the bayesian network and its model parameters, we are interested in finding the nodes
that contribute the most to our desired output. In other words, we want to maximize the conditional
probability of our output when other genes are intervened. We illustrate this further by modeling
drug intervention in an example bayesian network.
2.2.4 Drug Intervention
Drugs generally work by interacting with receptors on the surface of cells or enzymes within
cells. Binding to the target receptor site, they can either block the function of the protein (inhibitory
drug), or imitate it’s effect (enhancing drug).
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Suppose we have two drugs Drug-1 and Drug-2 that bind to the receptors A and B respectively
as shown in Figure 2.1, thereby disabling their functions further downstream. Mathematically, we
model this by setting the probability of that node having the value one equal to zero. That is, in the
case of Drug-1, we have, P (A = 1) = 0 and similarly for Drug-2, we have, P (B = 1) = 0.
Figure 2.1: Modeling the drug intervention in an example bayesian network. (Reprinted from [1])
Let us assume that our desired objective is to minimize the gene expression of E. Given the
two drug choices, we would like to find the more efficient drug for achieving this. In other words,
we are interested in determining the smaller of P (E = 1|A = 0) and P (E = 1|B = 0). If our
computations result in P (E = 1|A = 0) to be the smaller of the two, we conclude Drug-1 to be
the more effective one.
To calculate P (E|A) we compute:








C P (E|A,C)P (A,C)
P (A)
In a Bayesian network each variable is conditionally independent of all its non-descendants in the
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graph given the value of all its parents. Hence, P (E|A,C) = P (E|C). Substituting this into the
last expression and proceeding, we obtain:
∑
























B P (C|A,B)P (A)P (B))
)
P (A)




















Using the CPDs calculated earlier, we can compute (2.4), (2.5) and compare the two numbers,
based on which we can make a decision about whether to intervene with A or with B. Clearly, as
the network grows in size, computing these probabilities manually becomes tedious and intractable.
Shimony [19] showed that the probabilistic reasoning problems for general Bayesian networks are
NP-hard. Fortunately, there are algorithms for special cases that solve reasoning problems in time
that is a polynomial function of the number of variables. Message passing algorithms such as
Pearl’s message-passing propagation algorithm efficiently solve the inference problem in singly-
connected networks [20, 21]. We now briefly discuss the working of this algorithm.
2.2.5 Message-Passing Algorithm
Shimony [19] showed that the probabilistic reasoning problems for general Bayesian networks
are NP-hard. However, there are algorithms for special cases that solve reasoning problems in time
that is a polynomial function of the number of variables. In this section we review a polynomial-
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time algorithm called Pearl’s Message-Passing Algorithm, which is also known as Pearl’s belief
propagation algorithm. Pearl’s algorithm provides exact solutions to inference problems in singly-
connected graphs [22]. The algorithm exploits the loop-less feature in a singly-connected graph
that allows us to partition the graph in an efficient manner, greatly simplifying the reasoning prob-
lem.
Consider a Bayesian Network over a set of nodes X with a DAG G that is a singly-connected
directed graph. Let E ∈ X be a set of evidence variables such that E = e. For all random variables
X ∈ X , we define λ message, λ value, π message and π value as the following [21, 23]:
• λ message: The message a child Y passes to its parent X. It is denoted by λy(x).
• π message: The message a parent Z passes to its child X. It is denoted by πz(x).
• λ and π values: Each node has values of λ and π for each state that it may pass on.
An illustration of λ and π messages being exchanged in a graph is shown in Figure 2.2 below.
These messages and values are defined as follows.
Figure 2.2: λ messages and π messages in a singly-connected directed graph. (Reprinted from [1])
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where W1, ...,Wk are other parents of Y.





3. λ values :
(i) If X ∈ E and the observed values is X = x̂, for all x ∈ V al(X), define
λ(x) ≡
{
1 if x = x̂
0 else
(2.8)
(ii) If X /∈ E and X is a leaf, for all x ∈ V al(X), define λ(x) ≡ 1





4. π values :
(i) If X ∈ E and the observed value is X = x̂, for all x ∈ V al(X), define
π(x) ≡
{
1 if x = x̂
0 else
(ii) If X /∈ E and X is a root, for all x ∈ V al(X), define π(x) ≡ P (x)











where Z1, ...Zk ∈ Pa(X) are the parents of X.
5. If we define the messages and values as above, for all X ∈ X , x ∈ V al(X) we can calculate
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our required conditional probability given evidence e by :
P (x|e) = αλ(x)π(x) (where α is a normalizing constant)
We can compute λ(x), π(x) and P (x|e) for every random variable X ∈ X and for all values
x ∈ V al(X) using Algorithm 2 given below.
2 Message-Passing algorithm
1: function INITIALIZE NETWORK
2: for X ∈ X set λ(x) = 1
3: ∀Z ∈ Pa(X) set λX(z) = 1, ∀Y ∈ Ch(X) set πY (x) = 1
4: for every Root R ∈ X set π(x) = P (x), P (r|e) = P (r)
5: for W ∈ Ch(R) send_π_message(R,W )
6: end function
7:
8: function UPDATE NETWORK . New evidence V = v̂
9: E = E ∪ {V }
10: for v ∈ V al(V ), if v = v̂ set λ(v) = π(v) = P (v|e) = 1, else set = 0
11: ∀
(
Z ∈ Pa(V ) && Z /∈ E
)
send_λ_message(V, Z)
12: for Y ∈ Ch(V ) send_π_message(V, Y )
13: end function
14:
15: function SEND_λ_MESSAGE(Y,X) . λ message Y (child)→ X(parent)
16: Compute λY (x) using equation (2.6)
17: λ(x) =
∏
U∈Ch(X) λU(x), P̃ (x) = λ(x)π(x)
18: α =
∑
















23: function SEND_π_MESSAGE(Z,X) . π message Z(parent)→ X(child)
24: Compute πX(z) using equation (2.7)
25: if X /∈ E then
26: compute π(x) using equation (2.10)
27: P̃ (x) = λ(x)π(x)⇒ P (x|e) = 1
α
P̃ (x) where α =
∑
x P̃ (x)
28: for Y ∈ Ch(X) send_π_message(X, Y )
29: end if
30: if ∃ x such that λ(x) 6= 1 then
31: for
(






2.3 Breast Cancer Pathways
The Breast cancer pathway mainly consists of three important sub-pathways, the JAK/STAT,
the MAPK, and the PI3K/mTOR which all interact with each other.
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) cell signaling
pathway functions as the primary component of gene transcription and immune control. Abnormal
activation of the JAK/STAT pathway has been reported in various disease states [24], and in solid
tumors, constant phosphorylation of STAT3 has been demonstrated in breast cancer. JAKs employ
Cytokine receptors (CRLF2) and mediate tyrosine phosphorylation of STAT3 [25].
The mammalian target of rapamycin (mTOR), lies downstream of receptor phosphoinositide 3
kinase (PIK3CA) [26], and PI3K/Akt/mTOR is a well known pathway, which causes cell growth
and tumor proliferation in breast cancer [27]. Upregulated mTOR activates downstream riboso-
mal p70S6 kinase (RPS6KB1) and hyperphosphorylates Eukaryotic Translation Initiation Factor
4E (eIF4E) [28]. Hussain [29] showed a compelling biological connection between NF-κB and
PI3K/Akt pathway, where Akt activates the IKB kinase, a positive regulator of the survival factor
NF-κB. Studies have shown that Akt can directly inactivate pro-apoptotic factors such as BAD
[30].
Mitogen-Activated Protein Kinase (MAPK) families are well known to play an important
role in cellular functions such as proliferation, development and apoptosis. Raf activates the
MAPK/ERK kinase (MAP2K1), which then activates MAPK [31].
Wilson [32] displayed that SRC kinases are prime second messengers of HER2 (ERBB2),
and the connection between SRC activation and overexpression of ERBB2 has been reported in
breast carcinoma [33]. Ceramide (CERK) has been linked in diverse cellular processes, including
proliferation and apoptosis [34], and Phosphoglycolate Phosphatase (PGP) is a Protein Coding
gene that could increase the level of CERK in cells [35].
BCL-2 an apoptosis regulator is over-expressed in about 85% of ER-positive tumors [36]. Stud-
ies have shown that anamolous STAT3 signaling advances breast tumor growth through deregula-
tion of BCL-2, BIRC5 and MCL1 [37]. Targeting the mTOR pathway also resulted in decreased
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MCL1 expression postulating a link between them [38].
On the basis of the above biological information, we formulated the Breast Cancer signaling
pathway as shown in Figure 2.3. The gene interactions are represented by arrows, where a normal
arrow denotes activation and a red hammer arrow denotes inhibition.
Figure 2.3: Breast Cancer Signaling Pathway. An arrow indicates activation and a red hammer




In this section, we discuss the application of our model to select critical points of intervention
in the Breast Cancer pathway. We use real experimental data deposited in the NCBI database to
test the efficacy of our model. Analysis of expression data has three key uses: classifying diseases,
identifying decisive genes, and decoding biological pathways. Our choice of datasets meets these
pivotal requirements. Two datasets GSE2990 [39] and GSE6532 [40] were discretized and pooled
together. Each of these datasets contains the gene expression data obtained from the microarray
experiments carried out on primary breast tumors. Using this gene expression data we calculated
the CPDs of our Bayesian model using the method discussed in section 2.2.
Cancer is a disease in multicellular organisms that results from an imbalance between cell pro-
liferation and programmed cell death leading to the formation of tumors that become malignant.
Thus, a possible approach for treating cancer could be to enhance Apoptosis(cell death). It is
well known that the BCL-2 protein family, consisting of anti-apoptotic and pro-apoptotic mem-
bers, is involved in the regulation of apoptotic cell death. The anti-apoptotic members prevent
apoptosis by preventing the release of Cytochrome-c into the cytoplasm. On other hand, enhanced
expression of pro-apoptotic molecules can result in increased mitochondrial outer membrane per-
meability(MOMP), which leads to the release of Cytochrome-c. The hemeprotein Cyotchrome-c
then recruits Apaf-1 and pro-caspase-9 to form the Apoptosome, which triggers the Caspase 9/3
cascade, resulting in apoptosis [41]. In our signaling pathway, CERK and BAD are pro-apoptotic
genes, whereas, MCL1, BCL-2 and BIRC5 are anti-apoptotic genes.
We define a mathematical expression that incorporates the effect of both pro-apoptotic and
anti-apoptotic factors. Define the Apoptosis Ratio by:
Apoptosis Ratio =
Gene Expression (Pro-Apoptotic genes)
Gene Expression (Anti-Apoptotic genes)
(2.11)
Clearly, the higher the ratio, the greater the chances of Cytochrome-c release and consequently
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greater cell death.
Now, using ’s messaging passing algorithm discussed earlier, we computed this ratio condi-
tioned on the evidence set E, where E is the set of the genes being directly targeted by drugs. In
the next section, we discuss the results obtained.
Using the approach described above, we calculated the Apoptosis Ratio for two scenarios. First,
we assumed a single gene intervention and then we looked at a combination therapy involving the
simultaneous modulation of two genes.
2.4.2 Single Gene Intervention
We ran the algorithm for modulation using only one gene at a time and computed the cor-
responding Apoptosis Ratios as shown in Table 2.2. We then overlaid these ratios on the breast
cancer pathway as shown in Figure 2.4, and for elegance, we plotted only the most significant
genes in Figure 2.5. From the figure and the graph, it is evident that mTOR and Akt1 are the
most preferred nodes for single gene intervention. From the figure, it is also evident that both the
location of the gene and the number of crucial genes it intervenes with influence its apoptosis ratio.
2.4.3 Combination Therapy using Two Genes
Assuming that we can simultaneously intervene with a pair of genes, we ran the algorithm for
every set of two genes. Due to the large number of combinations, we only tabulated the most
significant ones in Table 2.3 and plotted them in Figure 2.6. From the graph, we infer that a
combination of mTOR and STAT3 is the most preferred pair for intervention purposes.
2.4.4 Drug Intervention
We now look at the drugs that are well known to intervene and bind specific genes in the
pathway, and compare computational results with the experimentally obtained ones.
APTSTAT3-9R is a specific STAT3-binding peptide that blocks STAT3 phosphorylation and re-
duces expression of STAT3 targets in various types of cancer cells [42]. Another STAT3 inhibitor
HO-3867 has been shown to disrupt the JAK/STAT3 signaling pathway thereby reducing the ex-
pression levels of both JAK and STAT3 [43]. Lapatinib, a reversible inhibitor of HER-2/ERBB2,
16
Table 2.2: Ratio of Apoptosis: Single gene intervention. (Reprinted from [1])






























































Figure 2.4: Apoptosis Ratios calculated by intervening different nodes independently. (Reprinted
from [1])
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Figure 2.5: Bar graph illustrating the Apoptosis Ratio calculated by intervening different nodes.
(Reprinted from [1])
has shown some success in different cancers [44]. LY294002, a selective PI3K inhibitor signifi-
cantly induced cell apoptosis in MCF-7 cells [45]. Temsirolimus is a potent mTOR inhibitor that
showed significant activity in vitro against a variety of cancer cells including MCF-7 breast cancer
cells [46]. An et al. [47] showed the suppression of human breast cancer cell line using U0126
which is a specific MEK inhibitor. Cryptotanshinone, a naturally occurring drug has been shown
to suppress the mTOR signaling pathway [48], and STAT3 signaling through blocking its dimer-
ization [49]. Using the above biological information, we tabulated the drugs and the gene(s) they
intervene in Table 2.4, and plotted the apoptosis ratio for different drugs.
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Table 2.3: Ratio of Apoptosis: Combination therapy involving two genes. (Reprinted from [1])
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Figure 2.6: Bar graph illustrating the Apoptosis Ratio calculated by intervening a set of two nodes.
(Reprinted from [1])
2.4.5 Single Drug Intervention
We calculated the apoptosis ratios when a single drug is used and plotted them in Figure 2.7.
2.4.6 Combination of Two Drugs
Considering the harmful side-effects of drugs, we restricted the maximum number of drugs per
combination to two in our theoretical analysis and experiments. Hence, here we are interested in
finding the drug combinations that maximize cell death with minimum side-effects. We calculated
the apoptosis ratios when a combination of two drugs is used and plotted them in Figure 2.8.
From the plots in Figure 2.7 and Figure 2.8, it is clear that Cryptotanshinone either by itself, or
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Figure 2.7: Bar graph illustrating the Apoptosis Ratio calculated when different drugs are used
independently. (Reprinted from [1])
in combination with other drugs results in greatly enhanced cell death. To verify this, we treated
MCF-7 breast cancer cell lines with these drug combinations and the experimental results agree
closely with the computational predictions. We now present the experimental results.
2.4.7 Experimental Validation
The theoretical results obtained above were validated using MCF–7 breast cancer cell lines
subjected to the various alternative drug treatments. The cell line was supplied to Dr. Jeffrey
Trent’s laboratory at the NIH from ATCC in 1996. This line is currently being used in the current
collaboration between Dr. Trent’s Institute, TGen, and the Texas A&M Center for Bioinformatics
and Genomic Systems Engineering. We used high–content fluorescent protein reporter imaging
22
Figure 2.8: Bar graph illustrating the Apoptosis Ratio calculated when a set of two drugs are used.
(Reprinted from [1])
method to track cell death in MCF–7 cells. We extracted cell processing dynamics using a two-
part data processing procedure introduced in Hua et. al. [50]. We condensed this data obtained
into expression profiles and represented as plots to interpret further.
The plots in Figure 2.9 show the cell killing produced in MCF7 breast cancer cell lines under the
effect of different drug combinations compared against the untreated cell line. Cryptotanshinone
has been used in each of the drug combinations and from the plots, it is clear that in each case,
impressive cell death occurs within 6-8 hours. Furthermore, all the drug combinations have more
than 95% apoptosis in 10 hours.
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Figure 2.9: Apoptosis fraction versus time(in hours) for different drug combinations. The
drug combinations in the legend from left to right are Cryptotanshinone, Cryptotanshinone +
APTSTAT3-9R, Cryptotanshinone + HO-3867, Cryptotanshinone + LY294002, Cryptotanshinone
+ Lapatinib and Untreated cell line. (Reprinted from [1])
Figure 2.10: Apoptosis fraction versus time (in hours) for different drug combinations. The drug
combinations in the legend from left to right are Untreated cell line, Paxlitaxel, Cryptotanshinone
+ Paxlitaxel. (Reprinted from [1])
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In order to compare our results with the standard therapy for breast cancer, we treated the
MCF7 cell line with Paxlitaxel [51] and its combination with Cryptotanshinone and compared
against untreated cell line. We plotted these results as shown in Figure 2.10. From the figure,
the drug is completely ineffective by itself, but upon the introduction of Cryptotanshinone, the
performance of cell death improves significantly over time. These results further strengthen our
argument that Cryptotanshinone substantially enhances cell death.
The ordering of the efficacy of cell death induction by the different combinations appears to be
in line with what is predicted by our computational approach. Hence, our computational results
agree closely with the experimentally obtained ones.
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3. IN SILICO DESIGN AND EXPERIMENTAL VALIDATION OF COMBINATION
THERAPY FOR PANCREATIC CANCER∗
3.1 Introduction
Pancreatic ductal adenocarcinoma (commonly referred to as pancreatic cancer) is the most
common malignancy of the pancreas. The American Cancer Society recently reported that the
number of deaths associated with pancreatic cancer has been increasing at an alarming rate making
it the third leading cause of cancer related deaths in the United States [4]. In 2018, it is estimated
that there will be 55,440 new diagnosed cases and 44,330 deaths linked to pancreatic cancer in the
United States alone. It is also estimated that by 2030, annual deaths due to pancreatic cancer will
exceed that of breast, prostate, and colorectal cancers [52].
The annual number of deaths for most cancers has decreased in recent decades, but the death
rate for pancreatic cancer has remained significantly flat. The absence of clinical progress in pan-
creatic cancer in comparison with other cancers is ascribed to a lack of success in developing novel
and effective therapies. This grim outlook for pancreatic cancer is linked to various reasons. Pan-
creatic cancer is usually diagnosed at advanced stages, which is usually due to an absence of early
symptoms and a lack of detecting/imaging techniques for early-stage tumors [53]. Pancreatic can-
cer also sets itself apart from other cancers because of its exceptional resistance to most traditional
medications, including radiotherapy and chemotherapy. This resistance stems from the complex-
ity pancreatic cancers carry at the genomic level, with diverse activated pathways and apparent
cross-talk [54].
Historically, biologists have captured cause-effect interactions between different biological
molecules using signaling pathways. Although marginal in nature, such information can provide
useful therapeutic pointers for diseases that result from a simple breakdown of such signaling. In
∗Parts of this section are reprinted with permission from H. Vundavilli, A. Datta, C. Sima, J. Hua, R. Lopes,
and M. Bittner, “In Silico Design and Experimental Validation of Combination Therapy for Pancreatic Cancer,”
IEEE/ACM Transactions on Computational Biology and Bioinformatics, vol. 17, no. 3, pp. 1010-1018, 2020, doi:
10.1109/TCBB.2018.2872573 c© 2020 IEEE
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the case of cancer, however, the success with this approach has been very limited mainly because of
the complexity of the possible breakdowns resulting in the manifestation of the disease [55]. Con-
sequently, in recent years there have been several attempts to holistically model the interactions
between different biological molecules of interest. Specific approaches used include Bayesian
networks [14], Differential equations [56], Boolean Networks [57] and Probabilistic Boolean net-
works [8].
In this work, we describe a methodology that utilizes current biological knowledge from the
literature to build a Boolean Network model of the pancreatic cancer pathway. We model the gene
interactions in the pathway using appropriate logic gates. We simulate this boolean network with
drugs at appropriate intervention points to calculate a “measure”, which is defined to capture the
extent of activation/deactivation of cell death. Such a measure can aid us in theoretically assessing
the effectiveness of drugs, provided the primary goal of therapy is to facilitate the death of cancer
cells.
3.2 Methodology
Gene regulatory networks, which describe the interactions between genes and other molecules,
play a pivotal role in orchestrating most biological processes such as cell proliferation, differenti-
ation, metabolism, and apoptosis. Understanding the mechanics of these networks can assist us in
dissecting the mechanisms of the diseases that result when these cellular processes deviate from
the norm [58]. Mathematical and computational methods have been developed for modeling these
gene interactions. These mathematical models have had some success in capturing some of the
complexities of biological networks [59].
One such widely used model is the Boolean Network (BN) model. Modeling of biological
interactions using BN has been successfully used for studying the Growth Factor signaling pathway
[57] and the Prostate Cancer pathway [6]. We now briefly review the key concepts needed for
modeling biological pathways with Boolean networks.
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3.2.1 Boolean Networks
In a Boolean network, each node can be in one of two binary states, inactive or active. It
is customary to assign a ‘0’ value to the inactive state and a ‘1’ value to the active state. In a
gene regulatory network (GRN), genes can be binarily quantized [60] and classified as either up-
regulated or down-regulated based on their gene expression levels. This switch-like behavior of
genes clearly can be modeled within a binary framework, thereby making boolean networks an
apparent choice to model GRNs. Furthermore, in a GRN, a gene is influenced by one or more
genes. This interaction among different genes can be modeled as a boolean logic function, where
the nodes represent the genes and the edges represent the interactions among the genes.
3.2.2 Modeling Abnormalities
Cancer is a collection of diseases in which abnormal cells are busy producing more cells, the
death of many produced cells, and the movement of cancer cells to other places in the body. This
abnormality can be caused by a malfunction in the normal signaling pathways leading to the loss
of cell cycle control and uncontrolled cell proliferation. One of the most common and well known
malfunctions is the mutation of a gene, which leads to its over- or under-expression. This aberration
can be modeled as a stuck-at fault in the BN. When a stuck-at fault occurs at a gene, its value gets
fixed at (0/1) and is no longer influenced by the activity status of other genes.
3.2.3 Modeling Drug Intervention
Drugs usually work by interacting with receptors on the surface of cells or on enzymes within
cells. They can either block the function of the protein (inhibitory drug), or induce it’s effect
(enhancing drug) by binding to the target receptor site. This interaction of the drug with a gene
can be mapped to a BN by either forcibly suppressing or enhancing the value of the gene at the
appropriate location.
We illustrate the type of modeling just discussed with the help of an example. Let us assume a
scenario where genes A and B independently activate gene C, genes C and D form a heterodimer
and activate gene E which then activates gene F. Furthermore, let us suppose that gene D is mutated
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and a drug precisely inhibits gene F. These interactions and the associated equivalent BN could be
represented as shown in Figure 3.1.
Figure 3.1: a) Example gene regulatory network. b) Boolean equivalent of the example gene
regulatory network. (Reprinted from [2])
We next analyze the signaling pathways and the specific drug intervention points associated
with pancreatic cancer.
3.3 Pancreatic Cancer Pathways
Signaling pathways supervise cellular processes such as growth, division, and death. Abnor-
mality in any of these controlled processes can lead to cancer. Abnormal paracrine and autocrine
signalling cascades in pancreatic cancer advance cell proliferation, invasion and metastasis.
Signalling molecules such as epidermal Growth Factor (EGF), insulin-like growth factor 1
(IGF1), heparin binding EGF like growth factor (HBEGF), and their respective tyrosine kinase
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receptors such as epidermal growth factor receptor (EGFR), IGF1 receptor (IGF1R), receptor
tyrosine-protein kinase (ERBB2), activate different pathways that strengthen pancreatic cancer
cells’ self-reliance and boost migration and invasion [61]. EGFR can form both homodimers and
heterodimers with ERBB2, and in the case of mutated Kirsten ras (KRAS), downstream signalling
has been shown to be excessively activated. In the presence of growth factor receptor-bound pro-
tein 2 (GRB2), these tyrosine kinase receptors were shown to be more effectively activated [62].
Liver kinase B1 (LKB1) is a well known serine/threonine kinase which senses changes in cel-
lular energy and adjusts metabolic processes by triggering its downstream kinase, AMP-activated
protein kinase (AMPK) [63]. These binding events make way for the activation of RAS, RAF
and mitogen-activated protein kinase (MAPK) signalling. In addition to these signaling cascades,
anti-apoptotic and pro-survival pathways such as signal transducer and activator of transcription 3
(STAT3), phosphatidylinositol 3-kinase (PI3K) and AKT are simultaneously activated [64]. Addi-
tionally, extracellular-regulated kinase (ERK1/2) and c-jun N-terminal kinase (JNK), members of
the MAPK family, have been demonstrated to regulate cell survival.
These pathways are supervised by a series of phosphatases, kinases and multiple exchange
proteins, and mutations in these pathways can lead to uncontrolled cell proliferation and eventually
cancer.
3.3.1 Drug Interventions
In the literature, scientists have established the specific receptors/enzymes where different
drugs intervene in a signaling pathway. We superimpose that data on our BN model to specify
the genes that will be inhibited by a particular drug. Before doing so, we first list our drugs of
interest and their specific targets.
HO-3867, a specific STAT3-binding peptide has been shown to block STAT3 phosphorylation
which results in the disruption of the JAK/STAT3 signaling pathway [65]. Temsirolimus is a selec-
tive mTOR inhibitor that has demonstrated significant activity in vitro against a variety of cancer
cells [66, 67]. Lapatinib, a reversible inhibitor of HER-2/ERBB2 and growth factor receptors has
shown some success in multiple cancers [68, 69]. LY294002 is a potent PI3K inhibitor that has
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Figure 3.2: Pancreatic cancer pathway. A black arrow denotes activation and a red arrow denotes
inhibition. The legends explain the role of different bounding boxes. (Reprinted from [2])
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notably induced cell death in cancer cells by impeding the PI3K/AKT pathway [70]. Cryptotanshi-
none (CPT), a naturally occurring drug has been shown to suppress STAT3 signaling in pancreatic
cancer cells by arresting the cell cycle in the G1-G0 phase, indicating that CPT is an effective
STAT3 inhibitor [71]. In the same study, the expression level of ERK1/2 was also significantly
inhibited by CPT. Cryptotanshinone has shown exceptional success in not only pancreatic cancer
cells but also in prostate cancer [48], human glioma [72], and chronic myeloid leukemia cells [73].
Consequently, we decided to include CPT in our list of drugs so that we could theoretically analyze
its beneficial effects, both while acting solo or in combination with other drugs.
Using the information presented above and the available literature, we constructed the gene reg-
ulatory network of pancreatic cancer as shown in Figure 3.2. The gene interactions are represented
by arrows, where a black arrow denotes activation and a red arrow denotes inhibition.
The boolean equivalent of this regulatory network is shown in Figure 3.3. The fault locations
are denoted by numbers in parentheses, where black numbers denote stuck-at-1 faults and blue
numbers denote stuck-at-0 faults. We next discuss the theoretical results obtained from the devel-
oped model and then present experimental results to support our theoretical conclusions.
Figure 3.3: Boolean equivalent of pancreatic cancer pathway. The numbers in parentheses
represent the identifying number assigned to a fault at that location. Here, black numbers denote




Using the Boolean model constructed above, we can now compare the different drug com-
binations and their efficacies. For each possible mutation/fault, the objective is to find the best
combination therapy that can alleviate the deleterious impact of that fault.
Referring to the Boolean model in figure 3, we have six inputs and six outputs. The inputs in-
clude two tumor suppressors ( PTEN, LKB1) and four growth factors (EGF, HBEGF, IGF, NRG1).
The outputs consist of pivotal genes (CCND1, BCL2, SRF-ELK1, FOS-JUN, SRF-ELK4, SP1) as-
sociated with and indicative of cell proliferation and apoptosis.
For mathematical analysis, we can represent these inputs and outputs as row vectors. A zero
corresponds to an inactive gene in the matching location, and on the other hand, a one corresponds
to an active gene. So the binary input and output vectors will be given by:
Input = [PTEN, LKB1, EGF, HBEGF, IGF, NRG1] and
Output = [CCND1, BCL2, SRF-ELK1, FOS-JUN, SRF-ELK4, SP1].
For the input [110000], the tumor suppressors are active and the growth factors are inactive,
and this input corresponds to an absence of proliferation and a non-reduction in apoptosis. In the
Boolean network with no faults, this input produces the output [000000], which also corresponds
to a lack of cell proliferation and a non-suppression of apoptosis. However, for the same input,
the network with faults will produce a different non-zero output vector. Our goal here is to guide
this non-zero output vector closer to the zero vector with the assistance of drugs. Biologically, this
is equivalent to driving a mutated pathway towards non-proliferation and unsuppressed apoptosis
using therapy.
The drugs we used in our simulations and experiments are, Cryptotanshinone (20 µM), LY294002
(10 µM), Temsirolimus (10 µM), Lapatinib (5 µM), and HO-3867 (10 µM). The drug dosage lev-
els of Lapatinib and Temsirolimus are those of human medical use, and the dosages for HO-3867,
33
LY294002, and Cryptotanshinone are at levels similar to the tests of their utilities on human and
canine cell lines. Once again, we can represent the activity status of the different drugs using a row
vector:
Drug = [Cryptotanshinone, LY294002,Temsirolimus, Lapatinib, HO-3867].
Each component of the drug vector will be one or zero according to whether that particular
drug is applied or not.
As stated above, we are interested in steering the output vector of a network with faults in
the direction of a desirable output vector. In order to quantify the dissimilarity between two output
vectors, we introduce a measure called Size Difference (SD). This quantity measures how different
two vectors are, and its value is proportional to the dissimilarity between the two vectors.
Let ā = (a1, . . . , an) and b̄ = (b1, . . . , bn) be two binary vectors. Then, we can count the
number of matches and mismatches at each bit location and construct a confusion matrix as shown
in Figure 3.4. Here the entries B and C keep count of the two types of possible mismatches
summed across all locations while the entries A and D keep count of the two types of possible
matches summed across all locations.
Figure 3.4: Example confusion matrix. (Reprinted from [2])








Since a higher size difference correlates with a higher deviation from the ideal output, the
outputs with greater SD would correspond to greater cell proliferation and/or reduced apoptosis
and possibly a higher risk of cancer.
The Boolean network when simulated across all possible faults and drug combinations yields
a matrix of SDs. An example matrix is shown below in Table 3.1. For each fault, we compare the
row entries, and the drug vector that corresponds to the row with the smallest value yields the most
desirable combination (for that fault). Similarly, in order to ascertain the most advantageous drug
combination across all faults, we add all the columns and choose the row corresponding to smallest
sum. In our example matrix, the second combination is favored across all faults and specifically
for faults 1 and 3.
Table 3.1
Example size difference matrix. (Reprinted from [2])
Fault 1 Fault 2 Fault 3
Drug combination 1 0.3 0.4 0.3
Drug combination 2 0.1 0.5 0.2
Drug combination 3 0.5 0.3 0.6
In this work, we additionally examined the existence of two faults and three faults simulta-
neously. Considering the harmful side-effects of drugs, we restricted the maximum number of
drugs per combination to two in our experiments. A simple algorithm to summarize the complete
method discussed is presented in Algorithm 3 below. The outputs 1 and 2 correspond to the best
drug combinations for each fault and across all faults respectively.
Using the method discussed above, we implemented the boolean network and simulated the
model in Matlab. We now present the theoretical results obtained followed by the experimental
results.
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3 Algorithm to find the best drug combinations
1: function
2: construct pathway from literature
3: design boolean network from pathway
4: simulate the boolean network
5: for each fault j do
6: for each drug combination i do
7: calculate SD(i, j)
8: end for
9: end for
10: output1(j) = arg mini SD(i, j)





We calculated the Size Difference for each combination of drug and fault. This arithmetic
was performed for one, two and three faults occurring simultaneously, and since there are 26
possible fault locations, a total of 26C1 + 26C2 + 26C3 = 2951 combinations were considered. We
plotted these values as a box plot as shown in Figure 3.5. Clearly, the drug combinations with
Cryptotanshinone yield small SD for a higher fraction of networks.
Furthermore, for each therapy, we find the average of size differences across all faults, and
call it an “overall measure". Since we are interested in finding the best drug combination, the
smallest overall measure corresponds to the most favorable combination. We first present the
overall measure values for at most one and at most two faults occurring simultaneously for each
drug combination in Table 3.2. We further present the overall measure for at most three faults
occurring simultaneously for each drug combination in Table 3.3. From the table, it is evident that
the bottom rows involving Cryptotanshinone resulted in very small measures, and the combination
of Cryptotanshinone with LY294002 had the lowest value. This mathematical output promises low
cell-proliferation and/or enhanced apoptosis in cells when Cryptotanshinone is used.
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Figure 3.5: Box plot of the size differences calculated across all faults for different drug combina-
tions. (Reprinted from [2])
3.4.3 Experimental Results
The theoretical results we obtained above were corroborated using experiments conducted on
HPAC pancreatic cells subjected to different drug treatments.
Using a high-content fluorescent protein reporter imaging method, we detected cell death in
HPAC cells. We extracted cell processing dynamics using a two-step data processing methodology
introduced in 2012 [50]. Subsequently, we condensed this acquired data into expression profiles
and plotted them to elucidate further.
The plots in Figure 3.6 display the cell killing produced in HPAC pancreatic cancer cell lines
under the effect of different drug combinations. The black line denotes the untreated cell line
which serves as a reference. Cryptotanshinone has been used in each of the drug combinations and
from the plots, it is apparent that in each instance, impressive cell death occurs within 6-8 hours.
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Table 3.2
The overall measure obtained for each of the drug combinations for at most one fault & two faults
occurring simultaneously. (Reprinted from [2])




Lapatinib + HO-3867 0.5323 0.5570
Temsirolimus 1.000 0.9982
Temsirolimus + HO-3867 0.9055 0.8693
Temsirolimus + Lapatinib 0.5721 0.6227
LY294002 0.6716 0.7089
LY294002 + HO-3867 0.6269 0.6299
LY294002 + Lapatinib 0.3881 0.4422
LY294002 + Temsirolimus 0.6716 0.7060
Cryptotanshinone 0.1443 0.1402
Cryptotanshinone + HO-3867 0.1443 0.1402
Cryptotanshinone + Lapatinib 0.0846 0.0899
Cryptotanshinone + Temsirolimus 0.1443 0.1384
Cryptotanshinone + LY294002 0.0149 0.0293
Moreover, all the drug combinations have more than 90% apoptosis in 15 hours. The fluorescent
images capturing cell death over time for Cryptotanshinone + LY294002 are shown in Figure 3.7.
From the figure, the tumor cells show increase in fluorescence and a lack of membrane integrity
over time and this demonstrates the cell killing carried out by Cryptotanshinone over time.
In order to compare our results with the standard therapy for pancreatic cancer, we treated
the PANC1 cell line with Gemcitabine [74], Gefitinib [75, 76] and their combinations with Cryp-
totanshinone and plotted these results in Figure 3.8. From the figure, the drugs are completely
ineffective by themselves, but upon the introduction of Cryptotanshinone, the performance of cell
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Table 3.3
The overall measure obtained for each of the drug combinations for at most three faults occurring
simultaneously. (Reprinted from [2])




Lapatinib + HO-3867 0.5852
Temsirolimus 0.9983
Temsirolimus + HO-3867 0.8473
Temsirolimus + Lapatinib 0.6705
LY294002 0.7460
LY294002 + HO-3867 0.6386
LY294002 + Lapatinib 0.4984
LY294002 + Temsirolimus 0.7419
Cryptotanshinone 0.1377
Cryptotanshinone + HO-3867 0.1377
Cryptotanshinone + Lapatinib 0.0957
Cryptotanshinone + Temsirolimus 0.1353
Cryptotanshinone + LY294002 0.0419
death improves significantly over time. These results further strengthen our argument that Cryp-
totanshinone substantially enhances cell death.
As a final observation, we identify that different drugs have different kinetics in Figure 3.6, and
we believe that there are primarily two reasons for this. Firstly, since the binding of a drug to a
specific receptor is a chemical process, the docking and activation probably takes different times
for different structures. Secondly, since different drugs act at different locations in the pathway,
the locations of these receptors might play an important role in the time course of the experiment.
39
Figure 3.6: Apoptosis fraction versus time (in hours) for different drug combinations. The drug
combinations in the legend from left to right are Cryptotanshinone, Cryptotanshinone + HO-3867,
Cryptotanshinone + LY294002, Cryptotanshinone + Lapatinib, Cryptotanshinone + Temsirolimus,
Untreated cell line. (Reprinted from [2])
Figure 3.7: Fluorescent images capturing cell death over time. (a) Without the presence of any
therapy, the tumor cells are intact and there is no fluorescence. (b,c) After adding Cryptotanshinone
+ LY294002, the tumor cells show a lack of membrane integrity with the presence of fluorescence
over time. The increase in fluorescence over time demonstrates the cell killing carried out by
Cryptotanshinone over time. (Reprinted from [2])
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Figure 3.8: Apoptosis fraction versus time (in hours) for different drug combinations. The drug
combinations in the legend from left to right are Gemcitabine, Gefitinib, Cryptotanshinone + Gem-
citabine, Cryptotanshinone + Gefitinib. (Reprinted from [2])
The ordering of the potency of cell death by the different combinations seems to be in line with
what is expected by our mathematical approach. Hence, our computational results concur with the
experimentally obtained ones.
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4. CRYPTOTANSHINONE INDUCES CELL DEATH IN LUNG CANCER BY TARGETING
ABERRANT FEEDBACK LOOPS∗
4.1 Introduction
Lung Cancer is globally the dominant cancer killer for both sexes. It is estimated that in the
United States alone, there will be 228,150 new diagnosed cases and 142,670 deaths linked to lung
cancer in 2019 [4]. In the last 40 years, the 5-year survival rate in the US has only increased to
20% from 12% showing a large room for improvement. This meager progress in the treatment of
lung cancer is mainly linked to its complex and heterogeneous molecular basis. Since lung cancers
advance through a multistage process comprising the evolution of multiple mutations, a deeper
understanding of the mutations at multiple levels and their significance has the potential to help
develop treatment strategies that can impact the diagnosis and treatment of the disease [77].
Multicellular organisms have developed highly sophisticated communication networks to inte-
grate and coordinate various biological processes. Potent negative feedback loops regulate these
processes in a controlled fashion and hence the elucidation of these feedback loops has surfaced
as an important research area for designing effective cancer therapies [78]. In recent times, scien-
tists have approached this drug-design problem as a control theoretic one and have used signaling
pathways to examine the cause-effect interactions between biological molecules and therapeutic
drugs [79]. The major approaches used to date for modeling gene regulatory network (GRN) inter-
actions include Differential equations [80], Bayesian networks [9, 81, 1], Boolean Networks [57],
and Probabilistic Boolean networks [82, 83]. Specifically, Boolean networks have lately shown
considerable success in modeling various cancers when modeling of biological feedbacks is not all
that crucial. On the other hand, they are not well-suited for capturing the typical feedback loops
in GRNs that administer many cellular processes. Therefore, we propose here a Modified Boolean
∗Parts of this section are reprinted with permission from H. Vundavilli, A. Datta, C. Sima, J. Hua, R. Lopes, and
M. Bittner, “Cryptotanshinone Induces Cell Death in Lung Cancer by Targeting Aberrant Feedback Loops,” in IEEE
Journal of Biomedical and Health Informatics, vol. 24, no. 8, pp. 2430-2438, 2020, doi: 10.1109/JBHI.2019.2958042
c© 2020 IEEE.
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Network that can address this crucial aspect. We make first use of the literature to construct the
lung cancer pathway. We then design the appropriate boolean network using the modified rules.
Lastly, we simulate this boolean network with drugs at appropriate intervention points to theo-
retically assess their effectiveness for killing cancer cells and validate our theoretical results with
experiments on cell lines.
4.2 Methodology
It is intuitively obvious that a better comprehension of the workings of gene regulatory net-
works could aid us in dissecting the mechanisms of diseases such as cancer that arise when cellular
processes behave in an aberrant fashion. In order to achieve this, several mathematical frameworks
have been developed to model these networks [59].
4.2.1 Boolean Network
Boolean Network (BN) modeling is one such framework that has recently proven useful for
studying multiple cancers [6, 2]. In a nutshell, for a Boolean network, we assign binary values
(‘0’ for an inactive state and ‘1’ for an active state) to each gene in the network and model the
interactions between them using boolean logic gates. This quantization of genes in binary space
is justified because genes are either down-regulated or up-regulated in the majority of cellular
processes [84]. When aberrations, such as those due to mutations, develop in controlled and well
regulated biological processes such as apoptosis, cells can multiply uncontrollably and possibly
form a tumor. We model these anomalies as faults in the network, where the mutated gene’s
activity status is stuck at some value and is non-responsive to the inputs from its regulator genes.
Although this traditional approach to BN modeling has provided some degree of success with
respect to biological relevance [85, 86], it is not well-suited for incorporating the feedback loops
that often arise in a biological context. Hence, in order to accommodate this, we propose a modified
boolean network. We now discuss the proposed modifications and then explain their benefits with
the help of an example.
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4.2.2 Modified Boolean Network
To date, we have used BNs to study the genes in a regulatory network that are abnormally
up-regulated or down-regulated and have used this knowledge to establish the decisive targets that
merit intervention. However, there are two major drawbacks with this classical approach.
First, this technique is incapable of distinguishing between the severity of two different gene
mutations. To circumvent this drawback, we introduce the following rules:
• Rule 1: Each node in the network can take values in the positive integer set Z+ ∈ {0, 1, 2, . . . }
where ‘0’ corresponds to the gene being down-regulated and the value n > 0 corresponds to
n units of the gene product.
• Rule 2: The output of an OR gate is the sum of its inputs and the output of an AND gate is
the minimum of its inputs, as shown in Figure 4.1.
Figure 4.1: Modified rules of ‘OR’ and ‘AND’ logic gates. The output of an OR gate is the sum
of its inputs (∈ Z+) and the output of an AND gate is the minimum of its inputs. (Reprinted from
[3])
The central idea of these rules is to not only qualitatively capture the up-regulation and down-
regulation of genes occurring in the network but also to quantify their activity status. Let us
elucidate this with the help of an example.
Consider a simple boolean network as shown in Figure 4.2a with possible faults occurring at F
and G. With the conventional approach, the scenarios of a fault occurring at either of F or G and
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that of faults at both F and G will produce the same output J = 1, thereby making the two scenarios
indistinguishable from the output J . On the other hand, with the new rules incorporated, a fault
occurring at either of F or G will return an output J = 1 whereas the simultaneous occurrence
of faults at both F and G will produce the output J = 2. This increased output can possibly
demonstrate enhanced proliferation and a faster-growing cancer.
The second drawback of classical Boolean network modeling stems from the fact that pivotal
genes in pathways oversee and control cellular processes by constraining the upstream activators.
This feedback necessitates a comparative approach where a gene applies brakes based on the dif-
ference between its abundance and the need for the particular gene product [87]. Clearly, the
traditional approach of BN modeling fails to incorporate this. Once again, we shall illustrate this
with the help of an example.
Consider a simple gene regulatory network (GRN) with 8 genes as shown in Figure 4.2b.
Suppose gene A activates gene B, and genes A, B dimerize and stimulate gene E, genes B and
E independently regulate gene C, gene E activates gene F which stimulates gene H and further
dimerizes with C to form G. Additionally, let us assume that genes C and H negatively regulate
genes A and D respectively through a feedback loop, gene E is mutated, and a drug inhibits gene F.
Using the conventional approach, we can construct the boolean equivalent of this GRN as shown in
Figure 4.2: a) Example boolean network with possible faults occurring at F and G. b) Example gene
regulatory network. c) The conventional boolean network of the example GRN. d) The Modified
boolean network of the example GRN. (Reprinted from [3])
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Figure 4.2c, but this network is missing the controlled feedbacks. Hence, in order to incorporate the
controlled feedback discussed above, we modeled the feedback using an integrator, a comparator,
and a delay block as shown in Figure 4.2d. Over time, the amount of gene products of genes C
and H will accumulate and an integrator computes this and feeds it to a comparator that determines
whether the brakes need to be applied. The delay block models the feedback delay that might occur
during inhibition. Here, k1, k2 and the amount of delay are design parameters.
Now having understood the methodology and examined its benefits, we apply it in the context
of lung cancer. First, we build the gene interaction network of lung cancer from the literature and
then simulate it using the framework discussed.
4.3 Lung Cancer Pathways
Lung cancer develops through a multistage process involving the progression of multiple ge-
netic aberrations. These abnormalities mainly occur in the three important sub-pathways, the
PI3K/AKT/mTOR, the JAK/STAT, and the RAS/RAF/ERK which all connect and interact with
each other [88].
The PI3K/AKT/mTOR pathway is a critical signal transduction pathway that is a key player in
the regulation of proliferation, differentiation, and survival of cells [89]. Mutations in this path-
way have been reported in various lung cancers. This pathway is activated downstream through
tyrosine kinase receptors including epidermal growth factor receptor (EGFR), insulin-like growth
factor 1 (IGF1), and receptor tyrosine-protein kinase (ERBB2) [90]. Activated receptor tyrosine
kinases engage PI3K to phosphorylate PIP2 to PIP3 which in turn recruits the serine-threonine
kinase AKT. AKT controls the expression of EGFR through a negative feedback. AKT also in-
hibits the tuberous sclerosis complex 1/2 (TSC1/2) which indirectly activates mTOR, a key man-
ager of cell growth and metabolism. Adenosine monophosphate-activated protein kinase (AMPK)
is an energy sensor in the cell which when activated by Metformin, a well known anti-diabetic
drug, phosphorylates TSC1/2 which in turn inhibits mTOR [91]. Upregulated mTOR activates
downstream ribosomal p70S6 kinase (RPS6KB1) which promotes growth signaling and regulates
Insulin Receptor Substrate 1 (IRS1) through a negative feedback loop [92].
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The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway plays
the role of a fundamental block in immune control and gene transcription. Abnormal activation of
the JAK/STAT pathway has been reported in multiple cancers. JAKs employ receptors and mediate
phosphorylation of STAT3 [93].
Finally, the RAS/RAF/ERK pathway (MAPK pathway) is an intracellular pathway that is in-
tegral in the cellular proliferation, differentiation, survival, and apoptosis. When stimulated aber-
rantly, this pathway can induce tumorigenesis and has been linked with multiple malignancies [94].
EGFR is an important tyrosine kinase receptor involved in the induction of the MAPK pathway.
RAS is a protein that is crucial for EGFR signaling whose mutations can activate downstream cas-
cade despite the regulation of EGFR. RAF is a downstream protein of RAS which upon activation
phosphorylates MEK and subsequently ERK [95]. The gene ERK promotes growth signaling and
also regulates GRB2/SOS activation through a negative feedback loop [96].
In the literature, there is generally broad agreement among scientists about the specific loca-
tions of receptors/genes where different drugs intervene in a signaling pathway. We tabulate the
list of drugs of interest to us and their targets in Table 4.1, along with the relevant references. The
arrows in the parentheses represent whether a drug inhibits (↓) or activates (↑) its target(s).
Table 4.1: Drugs used and their gene intervention points. (Reprinted from [3])
Drug Gene(s) targeted References
HO-3867 STAT3 (↓) [65]
LY294002 PIK3CA (↓) [70]
Temsirolimus mTOR (↓) [67]
Metformin AMPK (↑) [97]
Cryptotanshinone STAT3 (↓) + ERK (↓) [71, 48]
Lapatinib EGFR (↓) + ERBB2 (↓) [68, 69]
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Figure 4.3: Lung cancer signaling pathway. A black arrow denotes activation, a red arrow
denotes inhibition, and a dashed-red arrow denotes negative feedback. The legends explain the
role of different bounding boxes. Growth factors are signaling proteins that promote cell-growth,
survival, and differentiation. Receptors are proteins which bind to ligands such as growth receptors
and cause responses in the immune system. They also play an important role in signal transduction
and immunetherapy. Reporter genes are genes that help us in reporting expression levels and
activity of important processes such as cell growth and apoptosis. (Reprinted from [3])
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Using the above-discussed information available from the literature, we constructed the gene
regulatory pathway of lung cancer as shown in Figure 4.3. The gene interactions are represented
by arrows, where a black arrow denotes activation and a red arrow denotes inhibition. Using
the methodology discussed earlier, we constructed the boolean equivalent of this gene regulatory




Utilizing the Boolean model constructed in Figure 4.4 and the methodology discussed, when
the growth factors (EGF, HBEGF, IGF, NRG1) are present, the proliferation of cells measured
using the genes SRF-ELK4, FOS-JUN, SP1, SRF-ELK1, and BCL2 is controlled with the help of
the negative feedback loops present at AKT, ERK1/2, and RPS6KB1 genes. As discussed earlier,
we modeled each of these negative feedback loops as a cascade of an integrator and a comparator.
In Figure 4.4, k1, k2, and k3 are model parameters which decide whether to apply the brakes or
not. However, if a gene is mutated (over-expressed or under-expressed), the feedback loops can
no longer keep the proliferation in check and this can possibly cause cancer. Hence, our goal here
is to find the best drug combination that can mitigate the damaging effect of the majority of the
abberations/faults. For our simulations, we chose k1 = k2 = k3 = 50.
As discussed in the methodology section, each gene can assume a value in Z+ where ‘0’ cor-
responds to the gene being down-regulated and the value n > 0 corresponds to n units of the gene
product.
In case of inactive growth factors, all of EGF, HBEGF, IGF, and NRG1 are equal to 0, and in
the network with no faults, this corresponds to all the output genes, SRF-ELK4, FOS-JUN, SP1,
SRF-ELK1, and BCL2 equal to 0. However, in a network with faults present, the output genes will
yield non-zero values.
Now, to assess the extent of abnormality in the network, we plot the sum of output genes’
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Figure 4.4: The Modified Boolean equivalent of lung cancer pathway. The numbers in paren-
theses represent the identifying number assigned to a fault at that location. Here, black numbers
denote stuck-at-1 faults and blue numbers denote stuck-at-0 faults. (Reprinted from [3])
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values over time and compute its Area Under Curve (AUC). Biologically, the AUC is comparable
to the total number of cells produced in that time. Clearly, if the output genes’ values are equal to
0, then the AUC in that scenario is equal to 0 and this corresponds to inactive cell proliferation.
Since non-zero output genes’ values correlate with a cancerous network, a higher AUC associates
with greater cell proliferation and/or reduced apoptosis and possibly a higher risk of cancer.
We now simulate our lung cancer network across all possible faults and drug combinations and
this will return a matrix (rows = faults, columns = drug combinations) of AUCs. For each fault, we
compare the entries in the corresponding row, and the drug combination that matches the column
with the smallest AUC yields the most desirable combination (for that fault). Similarly, in order
to determine the most potent drug combination across all possible faults, we sum all the rows and
select the column with the smallest value.
In this work, we also examined the existence of two faults, three faults, and four faults occurring
simultaneously. Considering the harmful side-effects of drugs, in our experiments, we restricted
ourselves to a maximum of three drugs per combination. Here, we provide the simulation results
for at most three drugs per combination.
Using the method discussed above, we implemented the boolean network and simulated the
model. We now present the theoretical results obtained followed by the experimental ones.
4.4.2 Theoretical Results
For our lung cancer model, we calculated the Area Under Curve for each combination of drug
and fault. This arithmetic was performed for one, two, three, and four faults occurring simultane-
ously, and since there are 24 possible fault locations, we examined a total of 24C1 + 24C2 + 24C3 +
24C4 = 12950 combinations of faults. Furthermore, as explained above, to find the most domi-
nant drug combination, we find an average AUC across all faults, and the smallest average AUC
corresponds to the most favorable combination. In Table 4.2, we present the normalized (with no
therapy as the reference) average AUC for each drug combination. Here, we present the values
for at most four faults occurring simultaneously. From the table, it is evident that the bottom rows
(27-42) involving Cryptotanshinone result in remarkable therapeutic success.
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Table 4.2
The normalized average AUC obtained for each of the drug combinations. (Reprinted from [3])




4 HO-3867 + Metformin 0.8904
5 Lapatinib 0.7849
6 Lapatinib + Metformin 0.7834
7 Lapatinib + HO-3867 0.7067
8 Lapatinib + HO-3867 + Metformin 0.7045
9 Temsirolimus 0.9951
10 Temsirolimus + Metformin 0.9951
11 Temsirolimus + HO-3867 0.8846
12 Temsirolimus + HO-3867 + Metformin 0.8846
13 Temsirolimus + Lapatinib 0.7767
14 Temsirolimus + Lapatinib + Metformin 0.7767
15 Temsirolimus + Lapatinib + HO-3867 0.6949
16 LY294002 0.9857
17 LY294002 + Metformin 0.9829
18 LY294002 + HO-3867 0.8834
19 LY294002 + HO-3867 + Metformin 0.8807
20 LY294002 + Lapatinib 0.7698
21 LY294002 + Lapatinib + Metformin 0.7666
22 LY294002 + Lapatinib + HO-3867 0.7018
23 LY294002 + Temsirolimus 0.9672
24 LY294002 + Temsirolimus + Metformin 0.9672
25 LY294002 + Temsirolimus + HO-3867 0.8696
26 LY294002 + Temsirolimus + Lapatinib 0.7468
27 Cryptotanshinone 0.2253
28 Cryptotanshinone + Metformin 0.2157
29 Cryptotanshinone + HO-3867 0.2253
30 Cryptotanshinone + HO-3867 + Metformin 0.2157
31 Cryptotanshinone + Lapatinib 0.1634
32 Cryptotanshinone + Lapatinib + Metformin 0.1597
33 Cryptotanshinone + Lapatinib + HO-3867 0.1634
34 Cryptotanshinone + Temsirolimus 0.2030
35 Cryptotanshinone + Temsirolimus + Metformin 0.2030
36 Cryptotanshinone + Temsirolimus + HO-3867 0.2030
37 Cryptotanshinone + Temsirolimus + Lapatinib 0.1450
38 Cryptotanshinone + LY294002 0.1498
39 Cryptotanshinone + LY294002 + Metformin 0.1340
40 Cryptotanshinone + LY294002 + HO-3867 0.1498
41 Cryptotanshinone + LY294002 + Lapatinib 0.1158
42 Cryptotanshinone + LY294002 + Temsirolimus 0.0771
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For a better visual depiction, we plotted a heat map of AUCs for two faults occurring simul-
taneously for different drug combinations. We ran the simulations using the same parameters as
provided in the codes online. In Figure 4.5, we have heat maps which are 24 × 24 matrices (for
each of 24 faults) for three scenarios: Untreated, Temsirolimus + Lapatinib, and Cryptotanshinone
+ LY294002. The color in each cell represents the magnitude of AUC for that combination of two
faults. Here, a color closer to red in the spectrum represents a higher AUC value and a color closer
to green in the spectrum represents a lower AUC value. From the figure, the mutated pathway
when treated with Temsirolimus + Lapatinib has a minimal effect, whereas, Cryptotanshinone +
LY294002 shows promising therapeutic outcome. Further, we also provide the heat maps for all
two-drug combinations in Figure 4.6.
We also plotted the sum of output genes’ values for the fault-free network with active growth
factors and the network with fault at ERK1/2 before and after it is treated with Cryptotanshinone
in Figure 4.7. From the figure, the network without mutations is stabilized when growth factors
are present. However, with a fault (at ERK1/2), the network is driven to an abnormally active state,
and upon introduction of Cryptotanshinone, the growth is controlled. This mathematical output
promises low cell-proliferation and/or enhanced apoptosis in cells when Cryptotanshinone is used.
4.4.3 Experimental Results
The theoretical results we obtained above were corroborated using experiments conducted on
H2073 and SW900 lung cancer cell lines subjected to different drug treatments. We used a high-
content fluorescent protein reporter imaging method and detected cell death in these cells. Then,
using a well-known two-step data processing methodology, we extracted cell processing dynamics
[50]. To demonstrate further, we condensed this collected data into expression profiles and plotted
them.
The plots in Figure 4.8 demonstrate the cell killing produced in the H2073 lung cancer cell
line using the intervention of different drug combinations. The black line denotes the untreated
cell line which serves as a reference. Cryptotanshinone (CRY) has been used in each of the drug
combinations and from the plots, it is apparent that in each instance, impressive cell death occurs
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Figure 4.5: Heat map of AUC values for two faults occurring simultaneously for different drug
combinations. The drug combinations (from top to bottom) are Untreated, Temsirolimus + Lap-
atinib, and Cryptotanshinone + LY294002. Here, a color closer to red in the spectrum represents
a higher AUC value and a color closer to green in the spectrum represents a lower AUC value.
(Reprinted from [3])
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Figure 4.6: Heat map of AUC values for two faults occurring simultaneously for different drug
combinations. Here, a color closer to red in the spectrum represents a higher AUC value and a








Figure 4.7: The plot of the sum of output genes’ values for the fault free network (with active
growth factors) and the network with fault at ERK1/2 before and after Cryptotanshinone is added.
(Reprinted from [3])
and we have around 85% or more apoptosis in 24 hours. Hence, our computational predictions
made using the modified boolean approach seem to be in line with the experimentally obtained
ones.
In order to further confirm the efficacy of Cryptotanshinone, we carried out experiments with
and without Cryptotanshinone on SW900 lung cancer cell line. From Figure 4.9, it is clear that
the drugs (Metformin and HO-3867) are rather ineffective by themselves, but upon the addition of
Cryptotanshinone in the mixture, we observe a remarkable increase in the efficacy of inducing cell
death. These results further strengthen our argument that Cryptotanshinone substantially enhances
cell death. As a side remark, we also note that the average AUC values of Metformin (compare
rows 2, 28) and HO-3867 (compare rows 3, 29) from Table 4.2 are in line with our experimental
results.
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Figure 4.8: Apoptosis fraction versus time (in hours) for different drug combinations on H2073
cancer cell line. The drug combinations in the legend from left to right are Untreated cell line,
Cryptotanshinone, Cryptotanshinone + HO-3867, Cryptotanshinone + Lapatinib, Cryptotanshi-
none + Temsirolimus, Cryptotanshinone + HO-3867 + Lapatinib, Cryptotanshinone + HO-3867 +
Temsirolimus, and Cryptotanshinone + Lapatinib + Temsirolimus. (Reprinted from [3])
Figure 4.9: Apoptosis fraction versus time (in hours) for different drug combinations on SW900
cancer cell line. The drug combinations in the legend from left to right are Untreated cell line, Met-




Biologists are always interested in identifying a few pivotal genes that can be controlled rather
than a large group of genes, since it is both tedious and expensive to test the efficacy of the latter.
In Section 2, we presented a mathematical framework to deduce the significant modulator genes
in a biological signaling pathway and applied it to the Breast Cancer pathway. For a single gene
intervention, our results showed mTOR as the most favourable target to achieve cell death. In the
case of simultaneous intervention using two genes, a combination therapy targeting mTOR and
STAT3 emerged as an outstanding modulator of cell death.
Most of the cancer treatments to date, for instance the drug Gleevec used to treat Chronic
Myeloid Leukemia (CML), have utilized kinase inhibitors to keep cell proliferation in check. Al-
though such a treatment does provide good results when the inhibitory action of the drug matches
the particular mutation present, the success is usually short-lived as the cell figures out a mecha-
nism to bypass the activity of that drug and/or additional mutations develop. On the other hand,
if one could bring about a robust induction of cell death, independent of the particular mutations
involved, then this might provide a very effective strategy for killing cancer cells. We believe that
a robust modulator of this type should be capable of reinforcing its own activity via a positive feed-
back type of mechanism. This is similar to what happens in a servomechanism in control theory
where to robustly achieve zero steady-state error in the presence of a persistent disturbance, one
includes an internal model of the disturbance in the feedback loop [98, 99]. Although the idea of
such an engineering approach to cancer therapy needs more thorough exploration, intuitively it is
quite appealing as the imbalance between cell proliferation and cell death in a mature multicellular
∗Parts of this section are reprinted with permission from H. Vundavilli, A. Datta, C. Sima, J. Hua, R. Lopes, and
M. Bittner, “Bayesian Inference Identifies Combination Therapeutic Targets in Breast Cancer,” IEEE Transactions on
Biomedical Engineering, vol. 66, no. 9, pp. 2684-2692, 2019, doi: 10.1109/TBME.2019.2894980 c© 2019 IEEE; and
H. Vundavilli, A. Datta, C. Sima, J. Hua, R. Lopes, and M. Bittner, “In Silico Design and Experimental Validation of
Combination Therapy for Pancreatic Cancer,” IEEE/ACM Transactions on Computational Biology and Bioinformatics,
vol. 17, no. 3, pp. 1010-1018, 2020, doi: 10.1109/TCBB.2018.2872573 c© 2020 IEEE; and H. Vundavilli, A. Datta, C.
Sima, J. Hua, R. Lopes, and M. Bittner, “Cryptotanshinone Induces Cell Death in Lung Cancer by Targeting Aberrant
Feedback Loops,” in IEEE Journal of Biomedical and Health Informatics, vol. 24, no. 8, pp. 2430-2438, 2020, doi:
10.1109/JBHI.2019.2958042 c© 2020 IEEE.
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organism is what leads to tumorigenesis, and this imbalance could be considered to be the error
signal that needs to be zeroed out to restore homoeostasis of the cell numbers.
Pancreatic cancer has a 5 year survival rate of 9%, whereas, that of breast cancer is about
90% [100]. This appallingly low rate of success is commonly attributed to its late detection and
the existence of multiple activated pathways with cross-talk. With the possibility for so many
different mutations, combination therapy appears to be a promising approach. However, since the
potential number of drug combinations is large, and conducting biological experiments is complex
and costly, an exhaustive method might not be a perfect strategy. Hence, it is crucial to devise
mathematical models and methods that can curtail the search space.
In Section 3, we presented a Boolean framework to deduce the effective drug combinations
in a biological signaling pathway. The approach discussed was then applied to the Pancreatic
Cancer pathway. For the cancer pathway with three potential mutations, our results showed that
Cryptotanshinone in combination with LY294002 resulted as the most favourable drug therapy to
attain apoptosis.
Cancer is a disease characterized by unsupervised cell growth and it often progresses by the
failure of the body’s natural control system [101]. Using negative feedback loops, cells regulate
proliferation, and a breakdown of this system leads to unchecked cell proliferation which may
result in the formation of tumors. The primary reason for this uncontrolled growth is generally
associated with mutations in genes, and diverse activated pathways with interference make the
regulation additionally difficult. Hence, to simultaneously intervene in multiple pathways, combi-
nation therapy appears to be an attractive choice [102]. However, just with six drugs, the number of
experiments to be conducted to decide the best combination is 26−1 = 63, which is a prohibitively
large number, both from the point of view of expense and the associated manual labor. Thus, we
need to develop methods that can predict via simulations the combinations that are promising.
In Section 4, we presented a Modified Boolean model to theoretically infer the potent drug
combinations to affect the time evolution of a biological network. We then applied the framework
to the Lung Cancer pathway. Our results showed that Cryptotanshinone in itself or in combination
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with other drugs resulted in significant improvement in terms of promoting apoptosis.
Three critical pathways, the JAK/STAT, the PI3K/mTOR, and the MAPK pathway interact
with one another and play significant roles in cell growth, survival, and differentiation in several
human cancers. The Phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR pathway has been strongly
implicated to play a key role in the promotion of cell survival and its alteration in multiple can-
cers and is associated with resistance to several types of therapy. In advanced cancers, the PI3K
mutation rate can increase remarkably in different tumour types. In ovarian cancer, for example,
PI3K/Akt/mTOR pathway is activated in a staggering 70% of the cases [103].
PI3K activates the downstream kinase AKT which activates the mTOR protein, an essential
node in cell growth. As a serine/threonine kinase and a downstream member of the PI3K/Akt
pathway, mTOR is an essential regulator of cell growth and its survival. PI3K is an enzyme that
phospohorylates certain components of the cell membrane. Upon phosphorylation, these compo-
nents bind to the protein Akt which becomes phosphorylated and activated. This upregulated Akt
then activates mTOR, which promotes cell growth and proliferation by stimulating protein synthe-
sis. In addition to receiving signals from Akt, mTOR keeps track of the environment of the cell for
the presence of nutrients and growth factors. mTOR pathway has the capacity to control growth
factor, estrogen-dependent and estrogen-independent, pathways which contribute to the patholog-
ical process and advancement of tumors. Hence, in recent years, a new approach in breast cancer
therapy has been to obstruct this mTOR pathway. To inhibit this pathway, research has focused
on developing mTOR inhibitors as therapeutic agents for patients with breast cancer. Pre-clinical
reports back inhibition of this pathway, and stage I–III trials associating inhibitors of the mTOR
pathway have been carried out in solid tumors. The drug Everolimus is a well known mTOR
inhibitor, and recently, FDA approved it for the treatment of HR-positive, HER2-negative breast
cancer [104].
Additionally, mutated PI3K pathway along with other activated pathways avert drugs from
carrying out the inhibitory effects by devising an escape mechanism that leads to resistance. In
the majority of cancers, one such pathway is the MAPK pathway (RAS/RAF/MEK/ERK cascade)
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where abnormal KRAS activity prompts a cascade of up-regulated genes that contribute to the
progression of cancer [105]. Abnormal KRAS activity has been shown to trigger many downstream
signaling pathways and plays a decisive role in the development and progression of multiple human
cancers including pancreatic cancer [106]. On account of these diverse activated pathways, a
combination of agents targeting multiple steps of the intracellular machinery has a better chance of
yielding a successful therapeutic outcome. In order to affect the PI3K pathway, we used LY294002,
a well known PI3K inhibitor. LY294002 was shown to exclusively block the PI3K pathway in
different cancers and indicated a good potential when used in combination therapy to fight gastric
cancer [107].
The Janus kinase (JAK)/STAT signaling plays an important role in cell growth, differentiation
and tumor invasion in diverse human cancers. This pathway is an epitome of biological interac-
tions where extracellular factors regulate gene expression [108]. The STAT family of transcription
factors integrate Cytokine and growth factor signaling to supervise a diverse array of cellular pro-
cesses. STAT3, a member of the STAT protein family of transcription factors, forms dimers in the
nucleus of cells and supervises the gene expressions of its target genes. The JAK/STAT pathway
is mostly activated in all human cancers including breast, pancreatic, and lung cancers.
Under ordinary physiological habitat, STAT3 activation is tightly controlled, but strong evi-
dence indicates that STAT3 is constitutively activated in many cancers and is a key transcription
factor that is oncogenic in human cells [109]. STAT3 was recently found to have a key role in
cultivating cancer stem cells in both in-vitro and in-vivo mouse tumor models. This result indi-
cates its crucial involvement in tumor initiation, progression and maintenance [110]. In pancreatic
cancer, activated STAT3 forms dimers, and this exhibited an advancement of pancreatic intraep-
ithelial neoplasia growth and PDAC development [111]. Moreover, a down-regulation of STAT3
significantly abated the invasion ability of pancreatic cancer cells in vitro [112].
Further, aberrant STAT3 is expressed in about 55% of Non-small cell lung cancer (NSCLC)
tumors and this evidence of STAT3’s indispensable role in the initiation and progression of tumors
makes it a pivotal target [113]. As a result, it is only natural to look for STAT3 inhibitors that can
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obstruct the dimerization of STAT3 and restrict cell growth and differentiation. Recently, the drug
Pyrimethamine, a STAT3 inhibitor was approved by the FDA. Khan [114] reported inhibition of
STAT3 activity by Pyrimethamine in breast cancer cells.
Cryptotanshinone is one of the active components of Salvia miltiorrhiza Bunge and a naturally
occurring compound derived from a traditional Chinese herb, and has been previously shown to
possess anti-tumor properties in various types of human cancer cells [115]. Chen [116] recently
showed that Cryptotanshinone suppressed the mTOR signaling pathway in MCF-7 breast cancer
cell lines. Cryptotanshinone inhibited the expression of cyclin D1 thereby arresting cells in the
G1 −G0 phase of the cell cycle and preventing proliferation.
Shin et. al. [48] corroborated the effectiveness of Cryptotanshinone on prostate cancer cell
lines, where it inhibited STAT3 signaling through blocking its dimerization and decreasing the
expression of its downstream target proteins. In pancreatic cancer cells, Ge et. al. [71] recently
demonstrated that Cryptotanshinone inhibited proliferation and significantly induced apoptosis and
cell cycle arrest via inhibition of the STAT3 pathway.
Cryptotanshinone has also been shown to decrease the expression of its downstream target
proteins such as cyclin D1, survivin, and Bcl-xL. Evista (Raloxifene·HCl), another well known
drug, is a selective estrogen receptor modulator, and is used for preventing osteoporosis and treat-
ing cases of ER positive breast cancer in postmenopausal women with high risk of invasive breast
cancer. Shi [49] reported the inhibition of STAT3 phosphorylation by Evista in multiple cell lines
including MCF-7. In the same vein our theoretical and experimental results demonstrated that
Cryptotanshinone when used in combination undoubtedly boosts cell death [117].
In view of the preceding discussion, the literature on cancer signaling and Cryptotanshinone
backs our computational result that Cryptotanshinone by itself and when used in combination is a
promising drug in multiple cancers including breast, pancreatic, and lung cancers. The computa-
tional predictions made in this work agree with the past experimental results, thereby demonstrat-
ing the effectiveness of our models. We conclude that applying these methodologies to various
biological signaling pathways could help the medical community in designing effective drugs,
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without having to rely solely on conducting costly experiments. Finally, we believe that these find-
ings can form a basis for the advancement of new and better methodologies for the drug design
and treatment of other cancers.
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